PT - JOURNAL ARTICLE AU - Salazar-Vizcaya, Luisa AU - Atkinson, Andrew AU - Kronenberg, Andreas AU - Plüss-Suard, Catherine AU - Kouyos, Roger AU - Kachalov, Viacheslav AU - Troillet, Nicolas AU - Marschall, Jonas AU - Sommerstein, Rami TI - The impact of public health interventions on the future prevalence of ESBL-producing <em>Klebsiella pneumoniae</em>: a population based mathematical modelling study AID - 10.1101/19012765 DP - 2019 Jan 01 TA - medRxiv PG - 19012765 4099 - http://medrxiv.org/content/early/2019/11/27/19012765.short 4100 - http://medrxiv.org/content/early/2019/11/27/19012765.full AB - Background Extended-spectrum betalactamase (ESBL-) producing K. pneumoniae is one of the most common causes of infections with antimicrobial resistant bacteria worldwide. The spread of colonization of humans with this pathogen is on the rise. The future prevalence of colonization with ESBL-producing K. pneumoniae, and the potential of public health interventions to lower it, remain uncertain.Methods Based on detailed data on antimicrobial consumption and susceptibility systematically recorded for over 13 years in a Swiss region, we developed a mathematical model to i) reconstruct the observed course of colonization with ESBL-producing K. pneumoniae; and ii) to assess the potential impact of public health interventions on future trends in colonization.Results Simulated prevalence of colonization with ESBL-producing K. pneumoniae stabilized in the near future when rates of antimicrobial consumption and in-hospital transmission remained stable in the main analyses (simulated prevalence in 2025 was 5.3% (5.0%-9.1%) in hospitals and 2.7% (2.1%-4.6%) in the community versus 5.6% (5.1%-9.5%) and 2.8% (2.2%-5.0%) in 2019). The largest changes in future prevalence were observed in simulations that assumed changes in overall antimicrobial consumption. When overall antimicrobial consumption was set to decrease by 50%, prevalence in 2025 declined by 89% in hospitals and by 84% in the community. A 50% decline in transmission rate within hospitals led to a reduction in prevalence of 43% in hospitals and of 13% in the community by 2025. Prevalence changed much less (≤9%) across scenarios with reduced carbapenem consumption. Assuming higher rates for the contribution from external sources of colonization, led to decreasing estimations of future prevalence in hospitals. While high uncertainty remains on the magnitude of these contribution, the best model fit suggested that as much as 46% (95% CI: 12%-96 %) of observed colonizations could be attributable to sources other than human-to-human transmission within the geographical setting (i.e., non-local transmission).Conclusions This study suggests that overall antimicrobial consumption will be, by far, the most powerful driver of future prevalence and that a large fraction of colonizations could be attributed to non-local transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by an institutional grant (CTU Forschungsgrant der Inselgruppe)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon request: http://www.anresis.ch/